Author: Admin

Developer

Orion Group Holdings, Inc. Announces Contract Awards of $16 Million

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of $16 Million

 

HOUSTON–(BUSINESS WIRE)–Nov. 30, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced three contract awards for its Marine segment totaling approximately 
$16 million.

In 
Texas, the Company has been awarded a contract valued at 
$7.1 million by the 
U.S. Army Corps of Engineers for dredging in the Freeport Harbor Channel. Work is expected to begin in the first quarter of 2022 and to be completed in the second quarter of 2022. The Company has also been awarded a contract valued at 
$4.1 million by a local port for a pipeline removal project related to future expansion. Work on this project is expected to commence late in the fourth quarter of 2021 and be completed during the second quarter of 2022.

In 
Florida, the Company has been awarded a contract by a private sector client for the installation of a bulkhead wall for shore protection. This project is valued at 
$5.2 million and will commence in the first quarter of 2022 with the work completed in the second quarter of 2022.

“We’re pleased to announce these project awards, particularly the one in the private sector space,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “We continue to be disciplined in our bidding approach as we add work to our 2022 backlog.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

Posted on by Admin


Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

 

  • Four Patients With Dry Age-Related Macular Degeneration Observed to Have Areas of Geographic Atrophy Which Diminished or Remained Unchanged Relative to Baseline for a Period of at Least 12 Months
  • All Four Patients Exhibited Improvements in Visual Acuity at 12 Months
  • Differences in Visual Acuity Between Treated and Untreated Eyes in all Cohort 4 Patients Remained Statistically Significant At 9, 12, and 15 Months

CARLSBAD, Calif.–(BUSINESS WIRE)–Nov. 30, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that restoration of retinal tissue was observed in a fourth patient enrolled in the Company’s Phase 1/2a clinical study of its lead product candidate, OpRegen. Retinal tissue restoration and improved visual acuity has now been observed in all four better vision patients treated in Cohort 4, where surgeons successfully covered the majority of the area of atrophy with a suspension of OpRegen cells. Outer retinal layer restoration, which was observed using clinical high-resolution Optical Coherence Tomography (OCT), was evidenced by the presence of new areas of retinal pigment epithelium (RPE) monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These new and additive findings continue to support the Company’s view that atrophic AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable. OpRegen is an allogeneic RPE cell transplant in development for the treatment of age-related macular degeneration (AMD) with geographic atrophy (GA), or dry (atrophic) AMD.

“After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients. We have put significant work into reviewing images from the remaining patient who had the majority of the area of atrophy covered by the OpRegen suspension at the time of surgical implant. I am pleased to report that at the scheduled Month 12 post-operative visit for this patient, although less prominent than the 3 previously reported cases due to a smaller area of atrophy at baseline, there is clear evidence of retinal restoration in some areas, and the total area of atrophy as calculated using square root transformation, or SQRT, is smaller than the size calculated at baseline,” stated Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, 
Barcelona Macula Foundation. “The finding of a fourth case of restoration further supports our goal of showing that atrophic age-related macular degeneration can be responsive to this type of cell therapy. Dry AMD is a progressive disease and halting or reversing an area of atrophy does not occur spontaneously, which we believe makes the durability and reproducibility of these changes unprecedented within the field. With 12 months of follow-up complete, I am eager to have these cases submitted for peer-reviewed publication.”

“We have treated 24 patients with OpRegen, 12 of which were not legally blind at baseline and represent our intended treatment population. Among these 12 patients, four received thorough coverage of OpRegen cells across the majority of the atrophic area and experienced a cessation or reversal of their areas of atrophy at 12 months and continue to be followed. These patients also experienced increases in their visual acuity in their treated eye. We believe these four patients represent the only examples of an experimental treatment for dry AMD which can reduce an area of atrophy in humans, rather than simply slow its growth,” added  Brian M. Culley, Lineage CEO. “Restoration of retinal tissue using cell therapy represents a paradigm shift compared to conventional approaches, which to date have only shown an unremarkable slowing of progression. In addition to being well tolerated to date, the durability of changes to areas of atrophy and improvements in visual acuity support the continued and rapid clinical development of OpRegen. Alongside our advisors, we currently are preparing for multiple engagements with FDA to discuss aspects of OpRegen’s designation, our manufacturing plans, and the design of a later-stage clinical trial to begin next year. We anticipate the first of these engagements will begin next month and continue in the first quarter of 2022.”

OpRegen Phase 1/2a Interim Clinical Trial Results

  • Retinal restoration, reported in four patients to date, persisted from over 12 months to greater than 3 years following treatment and continues to be followed.
  • Restoration was evidenced by the presence of new areas of RPE monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment.
    • Reductions, or no progression for at least 1 year, was observed in the total area of GA in all four of these better vision Cohort 4 patients.
  • Overall, using the Early Treatment Diabetic Retinopathy Study (EDTRS) assessment of best corrected visual acuity (BCVA), 7/12 (58%) of each of Cohort 4 patients’ treated eye were at baseline or better at 15 months or last time point, which extends beyond 3 years in some patients. In comparison, at the same time points, 8/12 (67%) were below baseline in those same patients’ fellow untreated eyes.
    • All four retinal restoration patients reported improvements in their visual acuity, which has been maintained for at least 12 months in all four of those patients.
  • Across the study, in patients with previously reported structural improvements in the retina, decreases in drusen density, and a trend toward slower GA progression in treated compared to untreated eyes continue to be present.
  • Evidence of durable engraftment of OpRegen RPE cells has extended to more than 5 years in the earliest treated patients, supporting the potential for OpRegen to be a one-time treatment.

Overall, OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events that have not been previously reported.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen is a registered trademark of 
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of 
Lineage Cell Therapeutics, Inc.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease that can blur the sharp, central vision in patients and is the leading cause of vision loss in people over the age of 60. There are two forms of AMD: dry (atrophic) AMD and wet (neovascular) AMD. Dry (atrophic) AMD is the more common of the two forms, accounting for approximately 85-90% of all cases. In atrophic AMD, parts of the macula get thinner with age and accumulations of extracellular material between Bruch’s membrane and the RPE, known as drusen, increase in number and volume, leading to a progressive loss of central vision, typically in both eyes. Global sales of the two leading wet AMD therapies were in excess of 
$10 billion in 2019. Nearly all cases of wet AMD eventually will develop the underlying atrophic AMD if the newly formed blood vessels are treated correctly. There are currently no 
U.S. Food and Drug Administration (FDA), or 
European Medicines Agency, approved treatment options available for patients with atrophic AMD.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immune-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential benefits of treatment with OpRegen in dry AMD patients with GA, the significance of clinical data reported to date from the ongoing Phase 1/2a study of OpRegen, including the findings of retinal tissue restoration, Lineage’s plans to meet with the FDA to discuss OpRegen’s clinical development, the potential utilization of OCT imaging to measure efficacy in a pivotal clinical trial of OpRegen for the treatment of dry AMD with GA, and the potential for Lineage’s investigational allogeneic cell therapies to provide safe and effective treatment for multiple, diverse serious or life threatening conditions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including the risk that treatment with OpRegen in dry AMD patients with GA may not provide the benefits anticipated, the risk that interim results from clinical trials may not be predictive of future results, including later clinical trial results, and that interim data from clinical trials may change as more patient data become available and are subject to audit and verification procedures, and risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
 Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
 Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

Russo Partners – Media Relations
 Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Harte Hanks to Uplist to the Nasdaq Global Market

Posted on by Admin


Harte Hanks to Uplist to the Nasdaq Global Market

Trading under the ticker “HHS” expected to begin on December 1, 2021

Research, News, and Market Data on Harte Hanks


AUSTIN, Texas, Nov. 30, 2021 /PRNewswire/ — Harte Hanks, Inc. (OTCQX: HRTH) (the “Company”), a leading global customer experience company, today announced that the Company has met the stringent financial, liquidity and corporate governance listing requirements of the Nasdaq Global Market® (“Nasdaq”), and the Company has been approved for listing on the Nasdaq.

Trading on Nasdaq is expected to commence at the market open on December 1, 2021, and the shares will trade under the ticker symbol “HHS”.  The Company’s shares will continue to trade on the OTCQX under the symbol “HRTH” until trading on the Nasdaq commences.  Shareholders are not required to take any action as a result of the uplisting and symbol change.

“Uplisting to the Nasdaq marks another major milestone for Harte Hanks,” said Harte Hanks’ Chairman of the Board of Directors Jack Griffin. “With the expanded audience of investors, increased access to liquidity, and the significant improvement in our financial performance, we are well positioned for future profitable growth. Harte Hanks traded under the ticker ‘HHS’ for nearly 50 years, from its IPO in 1972 through 2020, and returning to a national exchange and this longstanding ticker symbol is an important indication of the progress we have made.”

Chief Executive Officer Brian Linscott added, “Uplisting to the Nasdaq reflects the considerable progress that Harte Hanks has made and will serve as a great opportunity to expand the Company’s institutional shareholder base and to enhance the Company’s efforts to create long-term shareholder value.”

About Harte Hanks

Harte Hanks (OTCMKTS: HRTH) is a leading global customer experience company whose mission is to partner with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract, and engage their customers.

Using its unparalleled resources and award-winning talent in the areas of Customer Care, Fulfillment and Logistics, and Marketing Services, Harte Hanks has a proven track record of driving results for some of the world’s premier brands including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM among others. Headquartered in Austin, Texas, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific.

For more information, visit hartehanks.com.

As used herein, “Harte Hanks” or “the Company” refers to Harte Hanks, Inc. and/or its applicable operating subsidiaries, as the context may require. Harte Hanks’ logo and name are trademarks of Harte Hanks.

Cautionary Note Regarding
Forward-Looking Statements

Our press release contains “forward-looking statements” within the meaning of U.S. federal securities laws. All such statements are qualified by this cautionary note, provided pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements other than historical facts are forward-looking and may be identified by words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “seeks,” “could,” “intends,” or words of similar meaning. These forward-looking statements are based on current information, expectations and estimates and involve risks, uncertainties, assumptions, and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements. In that event, our business, financial condition, results of operations or liquidity could be materially adversely affected and investors in our securities could lose part or all their investments. These risks, uncertainties, assumptions and other factors include: (a) local, national and international economic and business conditions, including (i) the outbreak of diseases, such as the COVID-19 coronavirus and new variants thereof, which has curtailed travel to and from certain countries and geographic regions, created supply chain disruption and shortages, disrupted business operations and reduced consumer spending, (ii) market conditions that may adversely impact marketing expenditures and (iii) the impact of economic environments and competitive pressures on the financial condition, marketing expenditures and activities of our clients and prospects; (b) the demand for our products and services by clients and prospective clients, including (i) the willingness of existing clients to maintain or increase their spending on products and services that are or remain profitable for us, and (ii) our ability to predict changes in client needs and preferences; (c) economic and other business factors that impact the industry verticals we serve, including competition and consolidation of current and prospective clients, vendors and partners in these verticals; (d) our ability to manage and timely adjust our facilities, capacity, workforce and cost structure to effectively serve our clients; (e) our ability to improve our processes and to provide new products and services in a timely and cost-effective manner though development, license, partnership or acquisition; (f) our ability to protect our facilities against security breaches and other interruptions and to protect sensitive personal information of our clients and their customers; (g) our ability to respond to increasing concern, regulation and legal action over consumer privacy issues, including changing requirements for collection, processing and use of information; (h) the impact of privacy and other regulations, including restrictions on unsolicited marketing communications and other consumer protection laws; (i) fluctuations in fuel prices, paper prices, postal rates and postal delivery schedules; (j) the number of shares, if any, that we may repurchase in connection with our repurchase program; (k) unanticipated developments regarding litigation or other contingent liabilities; (l) our ability to complete anticipated divestitures and reorganizations, including cost-saving initiatives; (m) our ability to realize the expected tax refunds; (n) the realization of any benefits that may be derived from listing the Company’s common stock on Nasdaq and (o) other factors discussed from time to time in our filings with the Securities and Exchange Commission, including under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 which was filed on March 24, 2021. The forward-looking statements in this press release are made only as of the date hereof, and we undertake no obligation to update publicly any forward-looking statement, even if new information becomes available or other events occur in the future.

Investor Relations Contact:
Rob Fink
FNK IR
HRTH@fnkir.com
646-809-4048

SOURCE Harte Hanks, Inc.

Release – Flotek Announces Participation in Noble Capital Markets Virtual Road Show Series

Posted on by Admin


Flotek Announces Participation in Noble Capital Markets Virtual Road Show Series

 

HOUSTON, Nov. 29, 2021 /PRNewswire/ — Flotek Industries, Inc. (NYSE: FTK) today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for December 1, 2021.

Join Flotek Industries CEO John W. Gibson, Jr for this exclusive fireside chat moderated by Noble Senior Research Analyst Michael Heim, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for December 1, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here.

Noble’s research, as well as news and advanced market data on Flotek Industries is available on Channelchek.

About Flotek Industries, Inc.
Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. A technology-driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance. Flotek’s Chemistry Technologies segment develops, manufactures, packages, distributes, delivers, and markets high-quality cleaning, disinfecting and sanitizing products for commercial, governmental and personal consumer use. Additionally, Flotek empowers the energy industry to maximize the value of their hydrocarbon streams and improve return on invested capital through its green chemistry technologies and JP3’s real-time data platforms. Flotek serves downstream, midstream, and upstream customers, both domestic and international. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit www.flotekind.com.

About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com

About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: contact@channelchek.com

SOURCE Flotek Industries, Inc.

Dip Buying in 2021 Has Consistently Paid-Off, is it Different this Time?

Posted on by Admin 


	Image Credit: Pixabay (Pexels)

Will the Latest 2021 Stock Retrenchment Be a Variant from Previous Dips?

 

Greed has been rewarded in 2021.

Eight of the last nine market dips have been undone with more buying and higher prices. The ninth, we’re in the midst of right now. This year’s dips have not been huge; buyers came in early before a high percentage of gains had a chance to be erased. Dip-buyers have been rewarded. Does this latest dip represent an opportunity to commit more to the market? Or is it the beginning of a larger fall-off? This is what many investors are deciphering right now. Let’s look at what we know.

 

 

Last week’s holiday-shortened trading saw stocks fall, with the S&P 500 declining 1.89%, the DOW Industrials fell 2.02%, and the Russell 2000 Index which had been the outperformer in November fell off 3.83%.  If 2021 maintains its current pattern, this decline will soon be replaced by higher price levels and new records.

 

 

In the past, money flow from investors into markets often was the result of chasing momentum – buying when stocks are rising, selling when falling. Cash would flow into stocks and equity funds, at times with a frenzy, at a market peak. Conversely, sell-offs were met with further selling until the move exhausted itself. The overall market behavior has been different over the past 18-22 months and it has taken on a pattern worth understanding, especially that which has been happening since the beginning of this year.

 

 

Sell-offs or retrenchments this year have come about largely from Covid 19 related news. Surges in cases, the arrival of the Delta variant, and the most recent sell-off with the Omicron variant. Strong rallies have come from good news, including the expanded roll-out of vaccinations, travel accelerating, and case numbers coming down.

Investors caught on to what is working, causing the market to take on a pattern where it has only been sinking single digits (<10%) before buyers committed more money. With this, the question is whether the news that brought it down in recent days will become an economy (and market) killer. This market mover is once again Covid-19 related. As with the past, there is no level of certainty what havoc a virus or variant of a virus (Omicron) may produce. However, we know more about the overall coronavirus than we did yesterday, last month, and at any time last year. If the past experience is any indicator, the odds are decent that this won’t cause a killer blow to the economy, especially since early reports are that this is not as deadly as earlier strains.

 

Take-Away

The “buy the dip” strategy has paid off this year. For now, investors have been paid by injecting more cash into their positions each time there is a one-week price drop. Interestingly, all of the opportunities have been at higher and higher averages. This time may be different, but there isn’t any obvious reason to believe it will be.

As measured by the S&P 500, Dow Industrials, and Russell Small-Cap index, the market dropped last week. We will soon know whether the trend continues and 9 out of 9 sell-offs quickly recover or if this will become a deviation from the trend.

Suggested Reading:



Is it Wise to Buy on Dips?

Protein Infused Chewing Gum Could Cut Spread of Covid 19 and Variants





Can the Fed Stop Inflation?

Will Small-Cap Stocks Outperform in 2022?

 

Sources:

www.koyfin.com

https://www.thecut.com/2021/11/what-we-know-about-the-omicron-variant-so-far.html

 

Stay up to date. Follow us:

 

QuickChek – November 30, 2021

Posted on by Admin



Harte Hanks to Uplist to the Nasdaq Global Market

Harte Hanks, Inc. today announced that the Company has met the stringent financial, liquidity and corporate governance listing requirements of the Nasdaq Global Market® (“Nasdaq”), and the Company has been approved for listing on the Nasdaq.

Research, News & Market Data on Harte Hanks


Esports Entertainment Group’s ggCircuit Launches New Product: OMEGA

Esports Entertainment Group, Inc. and their ggCircuit brand today announced OMEGA, a new revolutionary product offering for B2B customers.

Research, News & Market Data on Esports Entertainment Group


Flotek Announces Participation in Noble Capital Markets Virtual Road Show Series

Flotek Industries announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for December 1, 2021

Research, News & Market Data on Flotek
Register for the event



Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a fourth patient enrolled in the Company’s Phase 1/2a clinical study of its lead product candidate, OpRegen

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from Lineage Cell Therapeutics



Comtech Telecommunications Corp. Awarded $3.5 Million for Cyber Training

Comtech announced that during its first quarter of fiscal 2022, it was awarded $3.5 million for cyber training

Comtech announced that during its first quarter of fiscal 2022, it was awarded a 5G Contract with a Canadian Tier-One Carrier

Research, News & Market Data on Comtech

Watch recent presentation from Comtech



Kratos Receives Initial Approximate $4 Million in Single Award Funding on New C5ISR Program Award with Total Potential $75 Million Program Value

Kratos Defense & Security Solutions announced that it has received the initial, approximate $4 million in funding on a new, single award, Command, Control, Communication, Computing, Combat System, Intelligence, Surveillance & Reconnaissance (C5ISR) program

Research, News & Market Data on Kratos



Orion Group Holdings, Inc. Announces Contract Awards

Orion announced four contract awards for its Concrete segment totaling approximately $28 million

Orion announced three contract awards for its Marine segment totaling approximately $16 million

Research, News & Market Data on Orion Group Holdings

Watch recent presentation from Orion Group Holdings



Voyager Digital Announces Participation in December Investor Events

Voyager Digital announced the Company’s participation in investor events in December 2021

Research, News & Market Data on Voyager

Watch recent presentation from Voyager

 

Stay up to date. Follow us:

 

Flotek Announces Participation in Noble Capital Markets Virtual Road Show Series

Posted on by Admin


Flotek Announces Participation in Noble Capital Markets Virtual Road Show Series

 

HOUSTON, Nov. 29, 2021 /PRNewswire/ — Flotek Industries, Inc. (NYSE: FTK) today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for December 1, 2021.

Join Flotek Industries CEO John W. Gibson, Jr for this exclusive fireside chat moderated by Noble Senior Research Analyst Michael Heim, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for December 1, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here.

Noble’s research, as well as news and advanced market data on Flotek Industries is available on Channelchek.

About Flotek Industries, Inc.
Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. A technology-driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance. Flotek’s Chemistry Technologies segment develops, manufactures, packages, distributes, delivers, and markets high-quality cleaning, disinfecting and sanitizing products for commercial, governmental and personal consumer use. Additionally, Flotek empowers the energy industry to maximize the value of their hydrocarbon streams and improve return on invested capital through its green chemistry technologies and JP3’s real-time data platforms. Flotek serves downstream, midstream, and upstream customers, both domestic and international. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit www.flotekind.com.

About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com

About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. channelchek.vercel.app email: contact@channelchek.vercel.app

SOURCE Flotek Industries, Inc.

Release – Comtech Telecommunications Corp. Awarded 5G Contract with Canadian Tier-One Carrier

Posted on by Admin


Comtech Telecommunications Corp. Awarded 5G Contract with Canadian Tier-One Carrier

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Nov. 30, 2021– 
November 30, 2021— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today, that during its first quarter of fiscal 2022, it was awarded a contract to provide Gateway Mobile Location Center and Location Management Function solutions which enable new positioning technologies for a Canadian tier-one mobile network operator’s 5G network.

“5G is the next generation of telecom infrastructure,” said  Fred Kornberg, Chairman of the Board and Chief Executive Officer of 
Comtech Telecommunications Corp. “Comtech’s 5G innovations will bring more and faster services to this Canadian carrier. We are proud to be at the forefront of this pioneering technology.”

The contract was awarded to Comtech’s Trusted Location group, a leading provider of precise device location, mapping and messaging solutions for public safety, mobile network operators, and enterprise solutions. Sold around the world to mobile network operators, government agencies, and Fortune 100 enterprises, our platforms locate, map, track and message. For more information, visit www.comtechlocation.com.

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Comtech Investor Relations:
631-962-7005
investors@comtech.com

Source: 
Comtech Telecommunications Corp.

Release – Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen

Posted on by Admin


Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

 

  • Four Patients With Dry Age-Related Macular Degeneration Observed to Have Areas of Geographic Atrophy Which Diminished or Remained Unchanged Relative to Baseline for a Period of at Least 12 Months
  • All Four Patients Exhibited Improvements in Visual Acuity at 12 Months
  • Differences in Visual Acuity Between Treated and Untreated Eyes in all Cohort 4 Patients Remained Statistically Significant At 9, 12, and 15 Months

CARLSBAD, Calif.–(BUSINESS WIRE)–Nov. 30, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that restoration of retinal tissue was observed in a fourth patient enrolled in the Company’s Phase 1/2a clinical study of its lead product candidate, OpRegen. Retinal tissue restoration and improved visual acuity has now been observed in all four better vision patients treated in Cohort 4, where surgeons successfully covered the majority of the area of atrophy with a suspension of OpRegen cells. Outer retinal layer restoration, which was observed using clinical high-resolution Optical Coherence Tomography (OCT), was evidenced by the presence of new areas of retinal pigment epithelium (RPE) monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These new and additive findings continue to support the Company’s view that atrophic AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable. OpRegen is an allogeneic RPE cell transplant in development for the treatment of age-related macular degeneration (AMD) with geographic atrophy (GA), or dry (atrophic) AMD.

“After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients. We have put significant work into reviewing images from the remaining patient who had the majority of the area of atrophy covered by the OpRegen suspension at the time of surgical implant. I am pleased to report that at the scheduled Month 12 post-operative visit for this patient, although less prominent than the 3 previously reported cases due to a smaller area of atrophy at baseline, there is clear evidence of retinal restoration in some areas, and the total area of atrophy as calculated using square root transformation, or SQRT, is smaller than the size calculated at baseline,” stated Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, 
Barcelona Macula Foundation. “The finding of a fourth case of restoration further supports our goal of showing that atrophic age-related macular degeneration can be responsive to this type of cell therapy. Dry AMD is a progressive disease and halting or reversing an area of atrophy does not occur spontaneously, which we believe makes the durability and reproducibility of these changes unprecedented within the field. With 12 months of follow-up complete, I am eager to have these cases submitted for peer-reviewed publication.”

“We have treated 24 patients with OpRegen, 12 of which were not legally blind at baseline and represent our intended treatment population. Among these 12 patients, four received thorough coverage of OpRegen cells across the majority of the atrophic area and experienced a cessation or reversal of their areas of atrophy at 12 months and continue to be followed. These patients also experienced increases in their visual acuity in their treated eye. We believe these four patients represent the only examples of an experimental treatment for dry AMD which can reduce an area of atrophy in humans, rather than simply slow its growth,” added  Brian M. Culley, Lineage CEO. “Restoration of retinal tissue using cell therapy represents a paradigm shift compared to conventional approaches, which to date have only shown an unremarkable slowing of progression. In addition to being well tolerated to date, the durability of changes to areas of atrophy and improvements in visual acuity support the continued and rapid clinical development of OpRegen. Alongside our advisors, we currently are preparing for multiple engagements with FDA to discuss aspects of OpRegen’s designation, our manufacturing plans, and the design of a later-stage clinical trial to begin next year. We anticipate the first of these engagements will begin next month and continue in the first quarter of 2022.”

OpRegen Phase 1/2a Interim Clinical Trial Results

  • Retinal restoration, reported in four patients to date, persisted from over 12 months to greater than 3 years following treatment and continues to be followed.
  • Restoration was evidenced by the presence of new areas of RPE monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment.
    • Reductions, or no progression for at least 1 year, was observed in the total area of GA in all four of these better vision Cohort 4 patients.
  • Overall, using the Early Treatment Diabetic Retinopathy Study (EDTRS) assessment of best corrected visual acuity (BCVA), 7/12 (58%) of each of Cohort 4 patients’ treated eye were at baseline or better at 15 months or last time point, which extends beyond 3 years in some patients. In comparison, at the same time points, 8/12 (67%) were below baseline in those same patients’ fellow untreated eyes.
    • All four retinal restoration patients reported improvements in their visual acuity, which has been maintained for at least 12 months in all four of those patients.
  • Across the study, in patients with previously reported structural improvements in the retina, decreases in drusen density, and a trend toward slower GA progression in treated compared to untreated eyes continue to be present.
  • Evidence of durable engraftment of OpRegen RPE cells has extended to more than 5 years in the earliest treated patients, supporting the potential for OpRegen to be a one-time treatment.

Overall, OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events that have not been previously reported.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen is a registered trademark of 
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of 
Lineage Cell Therapeutics, Inc.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease that can blur the sharp, central vision in patients and is the leading cause of vision loss in people over the age of 60. There are two forms of AMD: dry (atrophic) AMD and wet (neovascular) AMD. Dry (atrophic) AMD is the more common of the two forms, accounting for approximately 85-90% of all cases. In atrophic AMD, parts of the macula get thinner with age and accumulations of extracellular material between Bruch’s membrane and the RPE, known as drusen, increase in number and volume, leading to a progressive loss of central vision, typically in both eyes. Global sales of the two leading wet AMD therapies were in excess of 
$10 billion in 2019. Nearly all cases of wet AMD eventually will develop the underlying atrophic AMD if the newly formed blood vessels are treated correctly. There are currently no 
U.S. Food and Drug Administration (FDA), or 
European Medicines Agency, approved treatment options available for patients with atrophic AMD.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immune-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential benefits of treatment with OpRegen in dry AMD patients with GA, the significance of clinical data reported to date from the ongoing Phase 1/2a study of OpRegen, including the findings of retinal tissue restoration, Lineage’s plans to meet with the FDA to discuss OpRegen’s clinical development, the potential utilization of OCT imaging to measure efficacy in a pivotal clinical trial of OpRegen for the treatment of dry AMD with GA, and the potential for Lineage’s investigational allogeneic cell therapies to provide safe and effective treatment for multiple, diverse serious or life threatening conditions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including the risk that treatment with OpRegen in dry AMD patients with GA may not provide the benefits anticipated, the risk that interim results from clinical trials may not be predictive of future results, including later clinical trial results, and that interim data from clinical trials may change as more patient data become available and are subject to audit and verification procedures, and risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
 Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
 Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

Russo Partners – Media Relations
 Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Orion Group Holdings Inc. Announces Contract Awards of Approximately $28 Million

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $28 Million

 

HOUSTON–(BUSINESS WIRE)–Nov. 30, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced four contract awards for its Concrete segment totaling approximately 
$28 million.

The Company was recently awarded three contracts in the 
Dallas area, including a 
$3.8 million contract for a data center expansion, a 
$4.3 million contract for the construction of two cast-in-place retirement residential buildings, and a 
$5.6 million contract for a cold storage facility. All three projects are expected to commence in the first quarter of 2022 and be complete in the fourth quarter of 2022.

The Company also has been awarded a contract valued at 
$5.1 million to construct tilt-wall warehouses in its 
Houston market and a contract valued at 
$9.2 million to build a mixed-use office-retail-residential building. Work on both projects is expected to begin during the first quarter of 2022 and be completed by the first quarter of 2023.

“These awards continue to demonstrate our position as a leader for concrete construction projects in our key 
Texas markets,” said  Mark Stauffer, Orion’s President and Chief Executive Officer.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Release – Voyager Digital Announces Participation in December Investor Events

Posted on by Admin

 


Voyager Digital Announces Participation in December Investor Events

 

NEW YORK, Nov. 30, 2021 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) today announced the Company’s participation in the following investor events in December 2021:

               December 2nd – D.A. Davidson Virtual FinTech Conference

               December 2nd – OTC Small Cap Growth Virtual Conference

               December 7th – Keefe, Bruyette & Woods Innovation in Finance Conference

               December 8th – B Riley Securities’ Crypto Conference

For more information about investor events that Voyager will be participating in, please visit www.investvoyager.com/investorrelations/events.

About Voyager Digital Ltd.
Voyager Digital Ltd. (TSX: VOYG;OTCQX: VYGVF; FRA: UCD2) is a fast-growing, publicly traded cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 60 different crypto assets using its easy-to-use mobile application, and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Press Contacts

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

Omicron Variant Highlights Long-Term Vaccination Needs

Posted on by Admin

Tuesday, November 30, 2021

Biotechnology
Omicron Variant Highlights Long-Term Vaccination Needs

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

Refer to the company pages linked in the report below for research reports and company specific disclosures.

Omicron Variant Causes New Concerns. On November 26, the World Health Organization met to discuss a new variant of the virus that causes COVID-19. The variant, now known as Omicron (previously B1.1.359 or the South African variant), has led to travel restrictions and stricter border controls in several counties. Omicron contains over 30 mutational changes in the spike protein targeted by current vaccines, raising concerns over vaccine efficacy. The emergence of new variants is consistent with our expectations for COVID-19 and our view that new vaccines will be needed.

We Believe New Vaccines Will Be Necessary We have expected the current vaccines to bring the pandemic under control, but have questioned the breadth of long-term protection they would provide. Viruses often have genetic variations that cause new strains to emerge over time. We have compared this to the influenza virus, for which a new vaccine is required every year.

COVAXIN Could Be An Strong Option As COVID-19 Vaccination Becomes Routine Ocugen (OCGN) has Phase 3 data for approval of COVAXIN, a vaccine developed with classic killed-virus technology. COVAXIN gives a broad antibody response against multiple epitopes (regions) of the virus, and has data showing protection including variants. Covaxin has a long half-life at refrigerated temperatures and does not need to be frozen. We believe these are some of the technological and practical considerations that could make it a strong option.

Cocrystal Is Developing Two Protease Inhibitors Against The Virus Cocrystal (COCP) is using its proprietary RNA technology to develop a protease inhibitor that could block an enzyme needed for the virus to reproduce. This is an early step in the viral life cycle that would eliminate the virus before it could cause symptoms or be transmitted to others. A formulation for inhaled delivery is expected to begin clinical trials in 2022, followed by an oral formulation later in 2022.

Conclusion: Viruses typically mutate over time and new strains are to be expected. Omicron is the latest of several strains that have been emerging in various regions around the world. We believe vaccination against COVID-19 will become routine practice and require new products. We are reiterating our Outperform ratings on OCGN and COCP, two companies developing vaccines for the coming year and long term use.

COVID-19 Variant Causes New Fears On November 26, the World Health Organization officials met to discuss a new variant of SARS-CoV-2, the virus that causes COVID-19. Concern over this variant, now known as the Omicron variant (previously B.1.1.359 or the South African variant) has led to travel restrictions and stricter border controls in several counties.  

The Omicron strain contains over 30 mutational changes in the spike protein that the current vaccines were developed to recognize. This has led to concern that the variant may not recognized by the immune system in vaccinated people, and may cause break-though symptoms and lack of  protection. Omicron contains variations that are found in the Alpha and Delta variants, indicating that it may have been a more recent mutation.

We Have Always Expected New Vaccines To Be Needed  The current messenger RNA vaccines were first approved under Emergency Use  Authorizations. While we always believed they provided sufficient efficacy to end pandemic lockdown and control the pandemic, the durability of the response and efficacy against variants and future outbreaks was unknown.

The current vaccines were developed against a protein on the viral surface, known as the spike protein. Most viral spike proteins are subject to genetic variation and change over time. This is known as “genetic drift” and is one of the reasons that new influenza vaccines are needed every year. Large variations are known as “genetic shift” and have less cross-reactivity and less recognition by the immune system. Variants that result from genetic shift cause more severe symptoms and mortality.

Virologist have long predicted that the pandemic would be controlled, but the virus would remain in circulation throughout the world.   New variants could emerge over time, with  resistant strains that could avoid the immunity from vaccines. We continue to believe new vaccines  are needed for long-term protection, with routine vaccinations/boosters becoming part of standard medical practice.

COVAXIN Would Fit Well With The Shift To Routine Vaccination Programs  Ocugen has in-licensed COVAXIN, a vaccine against the SARS-CoV-2 virus made using using classic killed-virus methodology. This is an older technology that has been used to produce many anti-viral vaccines over the past decades. Covaxin produces a immune response against multiple regions of the entire virus, in contrast to the more specific spike protein in the current vaccines. The COVAXIN immune response includes recognition of regions that are highly conserved and not subject to genetic variation over time. The Phase 3 trial was conducted in India at a time when the Delta virus was circulating, and has shown efficacy against it and other variants.

In addition to its efficacy and differentiated immune response, COVAXIN only requires refrigerated storage. It has a long shelf life that makes it suitable for distribution to doctor’s offices and clinical settings that do not have capacity for vaccines that must be kept frozen. This fits with current medical practice and is less expensive to distribute than a frozen product.

Ocugen has been in discussions with the FDA for US approval and submitted an application for approval in Canada. Marketing approval will require a bridging study to show that the immune response in patients vaccinated in US today is the same as the response seen in the Phase 3 trial population. No endpoints to confirm efficacy or safety are needed.

An IND was submitted to begin the bridging study in October. An IND typically becomes effective in 30 days, however, Ocugen received notification of a “Clinical Hold” in November. This will delay the start of the trial. No reasons were given, and the company is awaiting comments from the FDA. We had allowed long timeframes for approval, so this delay to the start of the trial does not affect our valuation.

Cocrystal Is Developing Two Protease Inhibitors Against the Virus  Cocrystal is using its proprietary RNA technology to develop two protease inhibitors that could block an enzyme needed for the virus to reproduce inside an infected cell. These drugs act on an early step in the viral life cycle. This would eliminate or reduce the quantity of virus in the patient, preventing symptoms and transmission to the surrounding environment. Drugs based on protease inhibition have been successful in HIV, hepatitis, and other viral diseases. 

The first product, CDI-45205, is a protease inhibitor that uses intranasal/pulmonary delivery that is expected to begin Phase 1/2 studies in 2022. An orally administered version is expected to begin later in 2022.

Cocrystal Will Present Data At The WAC COVID-19 Conference.   Cocrystal’s President and Co-CEO, Dr. Sam Lee, has been invited to present data from the COVID-19 program at the World Antiviral Conference. This scientific meeting will feature the foremost experts in research, clinical practice, government regulation and policy. The conference will held in San Diego on November 30 to December 2, with Dr. Lee’s presentation scheduled for December 1 at 11:55 PST.    

Conclusion:  The emergence of new strains of SARS-CoV-2 is consistent with expectations from virologists and characteristic of viruses in the SARS family.   The full genetic sequence of the Omicron variant is expected to take several weeks to determine.  Further information about the variant’s transmission, resilience to the immune system, and severity of infection may become available at that time.  We believe this new variant is consistent with the need for new vaccines for COVID-19, and reiterate our Outperform ratings on OCGN and COCP.

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and noninvestment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months.

Ocugen (OCGN)

The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

The Company has attended Noble investor conference(s) in the last 12 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.

Cocrystal Pharma (OCGN)

The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

The Company has attended Noble investor conference(s) in the last 12 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Research Analyst focusing on the Biotechnology and Specialty Pharmaceuticals industry. 16 years of industry experience. BA in Economics from Tulane University and an MBA from Columbia Business School. FINRA licenses 7, 24, 63, 86, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest
I or someone in my household has a financial interest in the securities of the subject company or other companies mentioned in this report. This interest has been documented and made known to the Research Supervisor and Compliance.

NOBLE RATINGS DEFINITIONS % OF SECURITIES COVERED % IB CLIENTS
Outperform: potential return is >15% above the current price 94% 33%
Market Perform: potential return is -15% to 15% of the current price 6% 2%
Underperform: potential return is >15% below the current price 0% 0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
150 East Palmetto Park Rd., Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Life Science Partners is a division of Noble Capital Markets, Inc.
Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 24294

Euroseas (ESEA) – Another Time Charter Enhances Forward Cover

Posted on by Admin

Tuesday, November 30, 2021

Euroseas (ESEA)
Another Time Charter Enhances Forward Cover

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another short charter on the Oakland signed before a four year charter starts. Yesterday, two time charters on the Oakland 4,253 TEU intermediate were announced. The first one runs 60-90 days at a TCE rate of $130.0k/day and the second one runs for at least four years (with a three month redelivery window) at a TCE rate of $42.0k/day into 1Q2026. While down from recent highs, the time charters are positive for cash flow visibility.

    No change to our 2021 EBITDA estimate of $53.9 million based on TCE rates of $18.6k/day.  As discussed in recent notes, forward cover is full and the Corfu is repositioning toward China on a short charter prior to dry docking …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.